Pharmacokinetic and Pharmacodynamic Characteristics of β-Blockers: When Differences May Matter

Journal of Cardiac Failure

Volumn 12, Issue 3, 2006, Pages 177-181

  Metra, Marco ^a   Cas, Livio Dei ^a   Cleland, John G F ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DOBUTAMINE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PLACEBO; SOTALOL; XAMOTEROL;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG BINDING; DRUG FORMULATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SELECTIVITY; EDITORIAL; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART RATE VARIABILITY; HUMAN; INOTROPISM; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPID SOLUBILITY; MORTALITY; NORADRENALIN RELEASE; PRIORITY JOURNAL; SUDDEN DEATH; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DELAYED-ACTION PREPARATIONS; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL; PROPANOLAMINES;

EID: 33646393235     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.02.010     Document Type: Editorial

References (54)

1. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
2. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 112 (2005) 1825-1852
3. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
4. MERIT-CHF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-CHF). Lancet 353 (1999) 2001-2007
5. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
6. Flather M.D., Shibata M.C., Coats A.J., Van Veldhuisen D.J., Parkhomenko A., Borbola J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
7. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New Engl J Med 344 (2001) 1659-1667
8. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., et al., Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
9. Bristow M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101 (2000) 558-569
10. Metra M., Nodari S., D'Aloia A., Bontempi L., Boldi E., and Dei Cas L. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J 139 (2000) 511-521
11. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
12. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 336 (1990) 1-6
13. Asano K., Zisman L.S., Yoshikawa T., Headley V., Bristow M.R., and Port J.D. Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. J Cardiovasc Pharmacol 37 (2001) 678-691
14. Kindermann M., Maack C., Schaller S., Finkler N., Schmidt K.I., Laer S., et al. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 109 (2004) 3182-3190
15. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., and Dei Cas L. Differential effects of β-blockers in patients with heart failure. A prospective, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2000) 546-551
16. Metra M., Nodari S., D'Aloia A., Robertson A.D., Bristow M.R., and Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40 (2002) 1248-1258
17. Packer M. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. J Card Fail 9 (2003) 429-443
18. Massie B.M. A comment on COMET: how to interpret a positive trial?. J Card Fail 9 (2003) 425-428
19. Metra M., Nardi M., Giubbini R., and Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24 (1994) 1678-1687
20. Kubo T., Azevedo E.R., Newton G.E., Parker J.D., and Floras J.S. Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol 38 (2001) 1463-1469
21. Liggett S.B., Tepe N.M., Lorenz J.N., Canning A.M., Jantz T.D., Mitarai S., et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101 (2000) 1707-1714
22. Du X.J., Autelitano D.J., Dilley R.J., Wang B., Dart A.M., and Woodcock E.A. Beta-2-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101 (2000) 71-77
23. Zhu W., Zeng X., Zheng M., and Xiao R.P. The enigma of beta2-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly. Circ Res 97 (2005) 507-509
24. Communal C., Singh K., Sawyer D.B., and Colucci W.S. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100 (1999) 2210-2212
25. Ahmet I., Krawczyk M., Heller P., Moon C., Lakatta E.G., and Talan M.I. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110 (2004) 1083-1090
26. Bristow M.R., Feldman A.M., Adams Jr. K.F., and Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?. J Card Fail 9 (2003) 444-453
27. Coca SG, Buller GK. COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet 2003 Sep 27;362:1076; author reply 1077-8.
28. Gong H., Sun H., Koch W.J., Rau T., Eschenhagen T., Ravens U., et al. Specific β2AR blocker ICI 118,551 actively decreases contraction through a Gi-coupled form of the β2AR in myocytes from failing human heart. Circulation 105 (2002) 2497-2503
29. Poole-Wilson P.A. Commentary on the Carvedilol or Metoprolol European Trial (COMET). Am J Cardiol 93 9A (2004) 40B-42B
30. Gilbert E.M., Abraham W.T., Olsen S., Hattler B., White M., Mealy P., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94 (1996) 2817-2825
31. Azevedo E.R., Kubo T., Mak S., Al-Hesayen A., Schofield A., Allan R., et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 104 (2001) 2194-2199
32. Cohn J.N., Pfeffer M.A., Rouleau J., Sharpe N., Swedberg K., Straub M., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 (2003) 659-667
33. Domanski M.J., Krause-Steinrauf H., Massie B.M., Deedwania P., Follmann D., Kovar D., et al. A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 9 (2003) 354-363
34. Bristow M.R., Krause-Steinrauf H., Nuzzo R., Liang C.S., Lindenfeld J., Lowes B.D., et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 110 (2004) 1437-1442
35. Kukin M.L., Kalman J., Charney R.H., Levy D.K., Buchholz-Varley C., Ocampo O.N., et al. Prospective, randomized comparison of effect of long-term treatment with etoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99 (1999) 2645-2651
36. Nodari S., Metra M., and Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects ofatenolol vs. nebivolol. Eur J Heart Fail 5 (2003) 621-627
37. Dargie H.J. Beta blockers in heart failure. Lancet 362 (2003) 2-3
38. Hjalmarson A., and Waagstein F. COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet 362 (2003) 1077
39. Sanderson J.E., Leung L.Y., Chan S.K., Yip G.W., Fung J.W., and Yu C.M. Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?. Eur J Heart Fail 7 (2005) 874-877
40. Metra M., Torp-Pedersen C., Swedberg K., Cleland J.G., Di Lenarda A., Komajda M., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26 (2005) 2259-2268
41. Andersson B., Aberg J., Lindelow B., Tang M.S., and Wikstrand J. Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. J Card Fail 7 (2001) 311-317
42. Kukin M.L., Mannino M.M., Freudenberger R.S., Kalman J., Buchholz-Varley C., and Ocampo O. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol 35 (2000) 45-50
43. Aquilante CL, Terra SG, Schofield RS, Pauly DF, Hatton PS, Binkley PF, et al. Sustained restoration of autonomic balance with long but not short acting metoprolol in patients with heart failure. J Cardiac Fail. In press.
44. Notarius C.F., and Floras J.S. Limitations of the use of spectral analysis of heart rate variability for the estimation of cardiac sympathetic activity in heart failure. Europace 3 (2001) 29-38
45. Binkley P.F., Nunziata E., Haas G.J., Nelson S.D., and Cody R.J. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 18 (1991) 464-472
46. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93 (1996) 1043-1065
47. van de Borne P., Montano N., Pagani M., Oren R., and Somers V.K. Absence of low-frequency variability of sympathetic nerve activity in severe heart failure. Circulation 95 (1997) 1449-1454
48. Guzzetti S., Cogliati C., Turiel M., Crema C., Lombardi F., and Malliani A. Sympathetic predominance followed by functional denervation in the progression of chronic heart failure. Eur Heart J 16 (1995) 1100-1107
49. Nolan J., Batin P.D., Andrews R., Lindsay S.J., Brooksby P., Mullen M., et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98 (1998) 1510-1516
50. Huikuri H.V., Makikallio T.H., Peng C.K., Goldberger A.L., Hintze U., and Moller M. Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. Circulation 101 (2000) 47-53
51. Tulppo M., and Huikuri H.V. Origin and significance of heart rate variability. J Am Coll Cardiol 43 (2004) 2278-2280
52. Mortara A., La Rovere M.T., Pinna G.D., Maestri R., Capomolla S., and Cobelli F. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 36 (2000) 1612-1618
53. Goldsmith R.L., Bigger J.T., Bloomfield D.M., Krum H., Steinman R.C., Sackner-Bernstein J., et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 80 (1997) 1101-1104
54. Bullinga J.R., Alharethi R., Schram M.S., Bristow M.R., and Gilbert E.M. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail 11 (2005) 693-699